{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:24:33Z","timestamp":1794410673480,"version":"4.9.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Serono SAS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10815-025-03647-7","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:04:45Z","timestamp":1758899085000},"page":"4361-4373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of luteinizing hormone in the management of female infertility: A French Delphi consensus"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-8014","authenticated-orcid":false,"given":"Isabelle","family":"C\u00e9drin-Durnerin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Labrosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire Castello","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"de Buyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Paillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Cerceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Olivennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Jacquesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"6","key":"3647_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s43032-019-00137-x","volume":"27","author":"A Arroyo","year":"2020","unstructured":"Arroyo A, Kim B, Yeh J. Luteinizing hormone action in human oocyte maturation and quality: signaling pathways, regulation, and clinical impact. Reprod Sci. 2020;27(6):1223\u201352. https:\/\/doi.org\/10.1007\/s43032-019-00137-x.","journal-title":"Reprod Sci"},{"key":"3647_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312735","author":"OO Oduwole","year":"2021","unstructured":"Oduwole OO, Huhtaniemi IT, Misrahi M. The roles of luteinizing hormone, follicle-stimulating hormone and testosterone in spermatogenesis and folliculogenesis revisited. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312735.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3647_CR3","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.rbmo.2023.103369","volume":"47","author":"A La Marca","year":"2023","unstructured":"La Marca A, Longo M, Sighinolfi G, Grisendi V, Imbrogno MG, Giulini S. New insights into the role of LH in early ovarian follicular growth: a possible tool to optimize follicular recruitment. Reprod Biomed Online. 2023;47(6):103369. https:\/\/doi.org\/10.1016\/j.rbmo.2023.103369.","journal-title":"Reprod Biomed Online"},{"key":"3647_CR4","doi-asserted-by":"publisher","unstructured":"Longobardi S, Klinger FG, Zheng W, Campitiello MR, D'Hooghe T, La Marca A. Gonadotropin activity during early folliculogenesis and implications for polycystic ovarian syndrome and premature ovarian insufficiency: a narrative review. Int J Mol Sci 2024;25(14). https:\/\/doi.org\/10.3390\/ijms25147520.","DOI":"10.3390\/ijms25147520"},{"issue":"2","key":"3647_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4274\/jtgga.galenos.2024.2023-12-9","volume":"25","author":"N Kugelman","year":"2024","unstructured":"Kugelman N, Pooni A, Rotshenker-Olshinka K, Bellemare V, Digby A, Dahan MH. Impact of stimulation with luteinizing hormone activity on IVF outcomes in patients with polycystic ovary syndrome. J Turk Ger Gynecol Assoc. 2024;25(2):60\u20135. https:\/\/doi.org\/10.4274\/jtgga.galenos.2024.2023-12-9.","journal-title":"J Turk Ger Gynecol Assoc"},{"issue":"5","key":"3647_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1210\/jcem.83.5.4770","volume":"83","author":"Group\" TERHLS","year":"1998","unstructured":"Group\" TERHLS. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. J Clin Endocrinol Metab. 1998;83(5):1507\u201314. https:\/\/doi.org\/10.1210\/jcem.83.5.4770.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3647_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/humupd\/dmy019","volume":"24","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Santi D, Esteves SC, Andersen CY, Humaidan P, et al. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(5):599\u2013614. https:\/\/doi.org\/10.1093\/humupd\/dmy019.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"3647_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.rbmo.2020.08.035","volume":"42","author":"P Arvis","year":"2021","unstructured":"Arvis P, Massin N, Lehert P. Effect of recombinant LH supplementation on cumulative live birth rate compared with FSH alone in poor ovarian responders: a large, real-world study. Reprod Biomed Online. 2021;42(3):546\u201354. https:\/\/doi.org\/10.1016\/j.rbmo.2020.08.035.","journal-title":"Reprod Biomed Online"},{"issue":"6","key":"3647_CR9","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/humrep\/deab065","volume":"36","author":"E Bosch","year":"2021","unstructured":"Bosch E, Alviggi C, Lispi M, Conforti A, Hanyaloglu AC, Chuderland D, et al. Reduced FSH and LH action: implications for medically assisted reproduction. Hum Reprod. 2021;36(6):1469\u201380. https:\/\/doi.org\/10.1093\/humrep\/deab065.","journal-title":"Hum Reprod"},{"issue":"3","key":"3647_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.fertnstert.2011.06.061","volume":"96","author":"JN Hugues","year":"2011","unstructured":"Hugues JN, Masse-Laroche E, Reboul-Marty J, Boiko O, Meynant C, Cedrin-Durnerin I. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration. Fertil Steril. 2011;96(3):600\u20134. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.06.061.","journal-title":"Fertil Steril"},{"issue":"7\u20138","key":"3647_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10815-005-5998-8","volume":"22","author":"B Sonntag","year":"2005","unstructured":"Sonntag B, Kiesel L, Nieschlag E, Behre HM. Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART. J Assist Reprod Genet. 2005;22(7\u20138):277\u201383. https:\/\/doi.org\/10.1007\/s10815-005-5998-8.","journal-title":"J Assist Reprod Genet"},{"issue":"9","key":"3647_CR12","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1093\/humrep\/13.9.2612","volume":"13","author":"LG Westergaard","year":"1998","unstructured":"Westergaard LG, Wiberg N, Andersen CY, Laursen SB, Kliem A, Westergaard JG, et al. Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles. Hum Reprod. 1998;13(9):2612\u20139. https:\/\/doi.org\/10.1093\/humrep\/13.9.2612.","journal-title":"Hum Reprod"},{"key":"3647_CR13","unstructured":"EMA (2024) European Medicines Agency. Summary of product characteristics: Pergoveris. Accessed on October 3rd, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pergoveris-epar-product-information_en.pdf."},{"issue":"9","key":"3647_CR14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/humrep\/dex234","volume":"32","author":"F Zegers-Hochschild","year":"2017","unstructured":"Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017;32(9):1786\u2013801. https:\/\/doi.org\/10.1093\/humrep\/dex234.","journal-title":"Hum Reprod"},{"issue":"5","key":"3647_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/09513590.2011.633128","volume":"28","author":"KF Buhler","year":"2012","unstructured":"Buhler KF, Fischer R. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study. Gynecol Endocrinol. 2012;28(5):345\u201350. https:\/\/doi.org\/10.3109\/09513590.2011.633128.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"3647_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12958-021-00759-4","volume":"19","author":"A Conforti","year":"2021","unstructured":"Conforti A, Esteves SC, Humaidan P, Longobardi S, D\u2019Hooghe T, Orvieto R, et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19(1):91. https:\/\/doi.org\/10.1186\/s12958-021-00759-4.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"3647_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dew360","volume":"32","author":"P Humaidan","year":"2017","unstructured":"Humaidan P, Chin W, Rogoff D, D\u2019Hooghe T, Longobardi S, Hubbard J, et al. Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(3):544\u201355. https:\/\/doi.org\/10.1093\/humrep\/dew360.","journal-title":"Hum Reprod"},{"issue":"7","key":"3647_CR18","doi-asserted-by":"publisher","first-page":"e32829","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z. Use of delphi in health sciences research: a narrative review. Medicine (Baltimore). 2023;102(7):e32829. https:\/\/doi.org\/10.1097\/MD.0000000000032829.","journal-title":"Medicine (Baltimore)"},{"key":"3647_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.zefq.2022.04.025","volume":"172","author":"J Spranger","year":"2022","unstructured":"Spranger J, Homberg A, Sonnberger M, Niederberger M. Reporting guidelines for Delphi techniques in health sciences: a methodological review. Z Evid Fortbild Qual Gesundhwes. 2022;172:1\u201311. https:\/\/doi.org\/10.1016\/j.zefq.2022.04.025.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"1","key":"3647_CR20","doi-asserted-by":"publisher","first-page":"2174692","DOI":"10.1080\/01443615.2023.2174692","volume":"43","author":"G Barrenetxea","year":"2023","unstructured":"Barrenetxea G, Hernandez C, Herrero J, Martinez Navarro L, Munoz M, Rubio JM, et al. Use of gonadotropins in ovarian stimulation in Spain: delphi consensus. J Obstet Gynaecol. 2023;43(1):2174692. https:\/\/doi.org\/10.1080\/01443615.2023.2174692.","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"3647_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.rbmo.2018.09.019","volume":"38","author":"E Bosch","year":"2019","unstructured":"Bosch E, Bulletti C, Copperman AB, Fanchin R, Yarali H, Petta CA, et al. How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus. Reprod Biomed Online. 2019;38(1):118\u201330. https:\/\/doi.org\/10.1016\/j.rbmo.2018.09.019.","journal-title":"Reprod Biomed Online"},{"key":"3647_CR22","doi-asserted-by":"publisher","first-page":"797365","DOI":"10.3389\/fendo.2021.797365","volume":"12","author":"A Conforti","year":"2021","unstructured":"Conforti A, Tuttelmann F, Alviggi C, Behre HM, Fischer R, Hu L, et al. Effect of genetic variants of gonadotropins and their receptors on ovarian stimulation outcomes: a Delphi consensus. Front Endocrinol (Lausanne). 2021;12:797365. https:\/\/doi.org\/10.3389\/fendo.2021.797365.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3647_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10815-021-02077-5","volume":"38","author":"G Coticchio","year":"2021","unstructured":"Coticchio G, Behr B, Campbell A, Meseguer M, Morbeck DE, Pisaturo V, et al. Fertility technologies and how to optimize laboratory performance to support the shortening of time to birth of a healthy singleton: a Delphi consensus. J Assist Reprod Genet. 2021;38(5):1021\u201343. https:\/\/doi.org\/10.1007\/s10815-021-02077-5.","journal-title":"J Assist Reprod Genet"},{"key":"3647_CR24","doi-asserted-by":"publisher","unstructured":"Courbiere B, Le Roux E, Mathieu d'Argent E, Torre A, Patrat C, Poncelet C, Montagut J, Gremeau AS, Creux H, Peigne M, Chanavaz-Lacheray I, Dirian L, Fritel X, Pouly JL, Fauconnier A, On Behalf Of The PreFerBe Expert P. Oocyte vitrification for fertility preservation in women with benign gynecologic disease: French clinical practice guidelines developed by a modified Delphi consensus process. J Clin Med 2021;10(17). https:\/\/doi.org\/10.3390\/jcm10173810.","DOI":"10.3390\/jcm10173810"},{"issue":"5","key":"3647_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10815-023-02757-4","volume":"40","author":"I Feferkorn","year":"2023","unstructured":"Feferkorn I, Ata B, Esteves SC, La Marca A, Paulson R, Blockeel C, et al. The HERA (hyper-response risk assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization. J Assist Reprod Genet. 2023;40(5):1071\u201381. https:\/\/doi.org\/10.1007\/s10815-023-02757-4.","journal-title":"J Assist Reprod Genet"},{"issue":"11","key":"3647_CR26","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s10815-023-02918-5","volume":"40","author":"I Feferkorn","year":"2023","unstructured":"Feferkorn I, Santos-Ribeiro S, Ubaldi FM, Velasco JG, Ata B, Blockeel C, et al. The HERA (hyper-response risk assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization. J Assist Reprod Genet. 2023;40(11):2681\u201395. https:\/\/doi.org\/10.1007\/s10815-023-02918-5.","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"3647_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10815-023-03003-7","volume":"41","author":"I Feferkorn","year":"2024","unstructured":"Feferkorn I, Santos-Ribeiro S, Ubaldi FM, Velasco JG, Ata B, Blockeel C, et al. The HERA (hyper-response risk assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization. J Assist Reprod Genet. 2024;41(2):519\u201320. https:\/\/doi.org\/10.1007\/s10815-023-03003-7.","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"3647_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/09513590.2015.1102879","volume":"32","author":"A La Marca","year":"2016","unstructured":"La Marca A, Ferraretti AP, Palermo R, Ubaldi FM. The use of ovarian reserve markers in IVF clinical practice: a national consensus. Gynecol Endocrinol. 2016;32(1):1\u20135. https:\/\/doi.org\/10.3109\/09513590.2015.1102879.","journal-title":"Gynecol Endocrinol"},{"key":"3647_CR29","doi-asserted-by":"publisher","first-page":"675670","DOI":"10.3389\/fendo.2021.675670","volume":"12","author":"R Orvieto","year":"2021","unstructured":"Orvieto R, Venetis CA, Fatemi HM, D\u2019Hooghe T, Fischer R, Koloda Y, et al. Optimising follicular development, pituitary suppression, triggering and luteal phase support during assisted reproductive technology: a Delphi consensus. Front Endocrinol (Lausanne). 2021;12:675670. https:\/\/doi.org\/10.3389\/fendo.2021.675670.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3647_CR30","doi-asserted-by":"publisher","first-page":"1506332","DOI":"10.3389\/fendo.2024.1506332","volume":"15","author":"J Awwad","year":"2024","unstructured":"Awwad J, Peramo B, Elgeyoushi B, Melado L, Salame A, Chawla M, et al. FSH\/LH co-stimulation in advanced maternal age (AMA) and hypo-responder patients - Arabian gulf delphi consensus group. Front Endocrinol (Lausanne). 2024;15:1506332. https:\/\/doi.org\/10.3389\/fendo.2024.1506332.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3647_CR31","doi-asserted-by":"publisher","unstructured":"Blockeel C, Guivarc'h-Leveque A, Rongieres C, Swierkowski-Blanchard N, Porcu-Buisson G, Yazbeck C, Wyns C. From patient classification to personalized optimized treatment in ART: the AMPLITUDE Delphi consensus. Front Reproductive Health 2024;6. https:\/\/doi.org\/10.3389\/frph.2024.1467322.","DOI":"10.3389\/frph.2024.1467322"},{"key":"3647_CR32","doi-asserted-by":"publisher","first-page":"1397446","DOI":"10.3389\/frph.2024.1397446","volume":"6","author":"S Salehpour","year":"2024","unstructured":"Salehpour S, Aleyasin A, Moini A, Mousavifar N, Mohammadhossein N, Abdollahi Fard S, et al. Luteinizing hormone supplementation in controlled ovarian stimulation: the Iran Delphi consensus. Front Reprod Health. 2024;6:1397446. https:\/\/doi.org\/10.3389\/frph.2024.1397446.","journal-title":"Front Reprod Health"},{"issue":"3","key":"3647_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00001703-200206000-00004","volume":"14","author":"J Balasch","year":"2002","unstructured":"Balasch J, Fabregues F. Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol. 2002;14(3):265\u201374. https:\/\/doi.org\/10.1097\/00001703-200206000-00004.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"3","key":"3647_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1095\/biolreprod.107.064089","volume":"78","author":"KA Walters","year":"2008","unstructured":"Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol Reprod. 2008;78(3):380\u20139. https:\/\/doi.org\/10.1095\/biolreprod.107.064089.","journal-title":"Biol Reprod"},{"key":"3647_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1477-7827-12-128","volume":"12","author":"CY Andersen","year":"2014","unstructured":"Andersen CY, Ezcurra D. Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins. Reprod Biol Endocrinol. 2014;12:128. https:\/\/doi.org\/10.1186\/1477-7827-12-128.","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"3647_CR36","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.fertnstert.2014.07.766","volume":"102","author":"MD Werner","year":"2014","unstructured":"Werner MD, Forman EJ, Hong KH, Franasiak JM, Molinaro TA, Scott RT Jr. Defining the \u201csweet spot\u201d for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles. Fertil Steril. 2014;102(5):1312\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.07.766.","journal-title":"Fertil Steril"},{"issue":"3","key":"3647_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/humrep\/deh682","volume":"20","author":"JN Hugues","year":"2005","unstructured":"Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A, et al. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod. 2005;20(3):629\u201335. https:\/\/doi.org\/10.1093\/humrep\/deh682.","journal-title":"Hum Reprod"},{"issue":"2","key":"3647_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/humrep\/deg066","volume":"18","author":"E Loumaye","year":"2003","unstructured":"Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH \u201cceiling\u201d effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod. 2003;18(2):314\u201322. https:\/\/doi.org\/10.1093\/humrep\/deg066.","journal-title":"Hum Reprod"},{"key":"3647_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mce.2015.12.008","volume":"422","author":"L Casarini","year":"2016","unstructured":"Casarini L, Riccetti L, De Pascali F, Nicoli A, Tagliavini S, Trenti T, et al. Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell Endocrinol. 2016;422:103\u201314. https:\/\/doi.org\/10.1016\/j.mce.2015.12.008.","journal-title":"Mol Cell Endocrinol"},{"key":"3647_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-10-24","volume":"10","author":"LA Cole","year":"2012","unstructured":"Cole LA. hCG, the wonder of today\u2019s science. Reprod Biol Endocrinol. 2012;10:24. https:\/\/doi.org\/10.1186\/1477-7827-10-24.","journal-title":"Reprod Biol Endocrinol"},{"key":"3647_CR41","doi-asserted-by":"publisher","unstructured":"Hershko Klement A, Shulman A. hCG triggering in ART: an evolutionary concept. Int J Mol Sci 2017;18(5). https:\/\/doi.org\/10.3390\/ijms18051075.","DOI":"10.3390\/ijms18051075"},{"key":"3647_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051059","author":"C Theofanakis","year":"2017","unstructured":"Theofanakis C, Drakakis P, Besharat A, Loutradis D. Human chorionic gonadotropin: the pregnancy hormone and more. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18051059.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"3647_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mce.2005.11.026","volume":"246","author":"KM Menon","year":"2006","unstructured":"Menon KM, Nair AK, Wang L. A novel post-transcriptional mechanism of regulation of luteinizing hormone receptor expression by an RNA binding protein from the ovary. Mol Cell Endocrinol. 2006;246(1\u20132):135\u201341. https:\/\/doi.org\/10.1016\/j.mce.2005.11.026.","journal-title":"Mol Cell Endocrinol"},{"key":"3647_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.mce.2006.03.046","volume":"260","author":"KM Menon","year":"2007","unstructured":"Menon KM, Nair AK, Wang L, Peegel H. Regulation of luteinizing hormone receptor mRNA expression by a specific RNA binding protein in the ovary. Mol Cell Endocrinol. 2007;260:109\u201316. https:\/\/doi.org\/10.1016\/j.mce.2006.03.046.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"3647_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.fertnstert.2018.01.003","volume":"109","author":"Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Buhler K, Ferraretti AP, De Placido G, Mollo A, Fischer R, Humaidan P, International Collaborative Group for the Study of r-h LH","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Buhler K, Ferraretti AP, De Placido G, Mollo A, Fischer R, Humaidan P, International Collaborative Group for the Study of r-h LH. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;109(4):644\u201364. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.01.003.","journal-title":"Fertil Steril"},{"issue":"10","key":"3647_CR46","doi-asserted-by":"publisher","first-page":"e47217","DOI":"10.7759\/cureus.47217","volume":"15","author":"A Nagulapalli","year":"2023","unstructured":"Nagulapalli A, Vembu R, Pandurangi M, Nellepalli SR. Luteinizing hormone\/human chorionic gonadotropin receptor N312S single-nucleotide polymorphism and its impact on clinical and reproductive outcomes in assisted reproductive technology: a prospective cohort study. Cureus. 2023;15(10):e47217. https:\/\/doi.org\/10.7759\/cureus.47217.","journal-title":"Cureus"},{"key":"3647_CR47","doi-asserted-by":"publisher","first-page":"628169","DOI":"10.3389\/fendo.2021.628169","volume":"12","author":"G Ramaraju","year":"2021","unstructured":"Ramaraju G, Cheemakurthi R, Kalagara M, Prathigudupu K, Balabomma KL, Mahapatro P, et al. Effect of LHCGR gene polymorphism (rs2293275) on LH supplementation protocol outcomes in second IVF cycles: a retrospective study. Front Endocrinol (Lausanne). 2021;12:628169. https:\/\/doi.org\/10.3389\/fendo.2021.628169.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3647_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejogrb.2018.01.025","volume":"222","author":"G Ramaraju","year":"2018","unstructured":"Ramaraju G, Cheemakurthi R, Prathigudupu K, Balabomma KL, Kalagara M, Thota S, et al. Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: a cross sectional study. Eur J Obstet Gynecol Reprod Biol. 2018;222:119\u201325. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.01.025.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"3647_CR49","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3275\/8657","volume":"35","author":"D Carone","year":"2012","unstructured":"Carone D, Caropreso C, Vitti A, Chiappetta R. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH\/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols. J Endocrinol Invest. 2012;35(11):996\u20131002. https:\/\/doi.org\/10.3275\/8657.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"3647_CR50","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1210\/jcem.83.5.4770","volume":"83","author":"The European Recombinant Human LH Study Group","year":"1998","unstructured":"The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83(5):1507\u201314. https:\/\/doi.org\/10.1210\/jcem.83.5.4770.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3647_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/1471-0528.15269","volume":"126","author":"A Vitagliano","year":"2019","unstructured":"Vitagliano A, Saccone G, Noventa M, Borini A, Coccia ME, Nardelli GB, et al. Pituitary block with gonadotrophin-releasing hormone antagonist during intrauterine insemination cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2019;126(2):167\u201375. https:\/\/doi.org\/10.1111\/1471-0528.15269.","journal-title":"BJOG"},{"issue":"1","key":"3647_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/humrep\/del340","volume":"22","author":"I Cedrin-Durnerin","year":"2007","unstructured":"Cedrin-Durnerin I, Bstandig B, Parneix I, Bied-Damon V, Avril C, Decanter C, et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22(1):109\u201316. https:\/\/doi.org\/10.1093\/humrep\/del340.","journal-title":"Hum Reprod"},{"issue":"5","key":"3647_CR53","doi-asserted-by":"publisher","first-page":"CD005070","DOI":"10.1002\/14651858.CD005070.pub3","volume":"5","author":"MH Mochtar","year":"2017","unstructured":"Mochtar MH, Danhof NA, Ayeleke RO, Van der Veen F, van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF\/ICSI cycles. Cochrane Database Syst Rev. 2017;5(5):CD005070. https:\/\/doi.org\/10.1002\/14651858.CD005070.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3647_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12958-019-0460-4","volume":"17","author":"A Conforti","year":"2019","unstructured":"Conforti A, Esteves SC, Di Rella F, Strina I, De Rosa P, Fiorenza A, et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2019;17(1):18. https:\/\/doi.org\/10.1186\/s12958-019-0460-4.","journal-title":"Reprod Biol Endocrinol"},{"issue":"2","key":"3647_CR55","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","volume":"20","author":"E Bosch","year":"2020","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. The Eshre Guideline Group on ovarian stimulation. ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;20(2):hoaa009. https:\/\/doi.org\/10.1093\/hropen\/hoaa009.","journal-title":"Hum Reprod Open"},{"key":"3647_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejogrb.2023.01.012","volume":"283","author":"L Hua","year":"2023","unstructured":"Hua L, Wang C. Recombinant-luteinzing hormone supplementation in women during IVF\/ICSI cycles with GNRH-antagonist protocol: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023;283:43\u20138. https:\/\/doi.org\/10.1016\/j.ejogrb.2023.01.012.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3647_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1477-7827-12-17","volume":"12","author":"P Lehert","year":"2014","unstructured":"Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;12:17. https:\/\/doi.org\/10.1186\/1477-7827-12-17.","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"3647_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1185\/030079902125001344","volume":"19","author":"R Driebergen","year":"2003","unstructured":"Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin. 2003;19(1):41\u20136. https:\/\/doi.org\/10.1185\/030079902125001344.","journal-title":"Curr Med Res Opin"},{"key":"3647_CR59","unstructured":"Hugues J (2017) \u00c9volution des pr\u00e9parations commercialis\u00e9es \u00e0 effet folliculostimulant 2017;19(3):174\u2013180. https:\/\/doi.org\/10.1684\/mte.2017.0661. M\u00e9d Reproduc 19 (3):174\u2013180."},{"issue":"4","key":"3647_CR60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","volume":"69","author":"F de Barros","year":"2014","unstructured":"de Barros F, Le\u00e3o R, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics (Sao Paulo). 2014;69(4):279\u201393. https:\/\/doi.org\/10.6061\/clinics\/2014(04)10.","journal-title":"Clinics (Sao Paulo)"},{"key":"3647_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fendo.2019.00429","volume":"10","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Alam V, D\u2019Hooghe T, Sunkara SK. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol (Lausanne). 2019;10:429. https:\/\/doi.org\/10.3389\/fendo.2019.00429.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3647_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1477-7827-8-112","volume":"8","author":"P Lehert","year":"2010","unstructured":"Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol. 2010;8:112. https:\/\/doi.org\/10.1186\/1477-7827-8-112.","journal-title":"Reprod Biol Endocrinol"},{"issue":"10","key":"3647_CR63","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/humrep\/12.10.2133","volume":"12","author":"C Bergh","year":"1997","unstructured":"Bergh C, Howles CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod. 1997;12(10):2133\u20139. https:\/\/doi.org\/10.1093\/humrep\/12.10.2133.","journal-title":"Hum Reprod"},{"issue":"3","key":"3647_CR64","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/humrep\/15.3.520","volume":"15","author":"R Frydman","year":"2000","unstructured":"Frydman R, Howles CM, Truong F, The French Multicentre Trialists. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. Hum Reprod. 2000;15(3):520\u20135. https:\/\/doi.org\/10.1093\/humrep\/15.3.520.","journal-title":"Hum Reprod"},{"issue":"8","key":"3647_CR65","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/humrep\/15.8.1691","volume":"15","author":"R Schats","year":"2000","unstructured":"Schats R, Sutter PD, Bassil S, Kremer JA, Tournaye H, Donnez J. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group. Hum Reprod. 2000;15(8):1691\u20137. https:\/\/doi.org\/10.1093\/humrep\/15.8.1691.","journal-title":"Hum Reprod"},{"issue":"5","key":"3647_CR66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40618-014-0204-4","volume":"38","author":"PE Levi Setti","year":"2015","unstructured":"Levi Setti PE, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S, et al. Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. J Endocrinol Invest. 2015;38(5):497\u2013503. https:\/\/doi.org\/10.1007\/s40618-014-0204-4.","journal-title":"J Endocrinol Invest"},{"key":"3647_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fendo.2019.00614","volume":"10","author":"T Haahr","year":"2019","unstructured":"Haahr T, Dosouto C, Alviggi C, Esteves SC, Humaidan P. Management strategies for POSEIDON groups 3 and 4. Front Endocrinol (Lausanne). 2019;10:614. https:\/\/doi.org\/10.3389\/fendo.2019.00614.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3647_CR68","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.12688\/f1000research.10382.1","volume":"5","author":"P Humaidan","year":"2016","unstructured":"Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of \u201clow prognosis patients in Assisted Reproductive Technology\u201d and its proposed marker of successful outcome. F1000Res. 2016;5:2911. https:\/\/doi.org\/10.12688\/f1000research.10382.1.","journal-title":"F1000Res"},{"issue":"6","key":"3647_CR69","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","volume":"105","author":"G Poseidon","year":"2016","unstructured":"Poseidon G, Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.02.005.","journal-title":"Fertil Steril"},{"issue":"3","key":"3647_CR70","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/humrep\/deq361","volume":"26","author":"VK Genro","year":"2011","unstructured":"Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-Mullerian hormone levels are negatively related to follicular output raTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Hum Reprod. 2011;26(3):671\u20137. https:\/\/doi.org\/10.1093\/humrep\/deq361.","journal-title":"Hum Reprod"},{"key":"3647_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fendo.2019.00246","volume":"10","author":"M Grynberg","year":"2019","unstructured":"Grynberg M, Labrosse J. Understanding follicular output rate (FORT) and its implications for POSEIDON criteria. Front Endocrinol (Lausanne). 2019;10:246. https:\/\/doi.org\/10.3389\/fendo.2019.00246.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3647_CR72","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/humrep\/deh625","volume":"20","author":"G De Placido","year":"2005","unstructured":"De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod. 2005;20(2):390\u20136. https:\/\/doi.org\/10.1093\/humrep\/deh625.","journal-title":"Hum Reprod"},{"issue":"Suppl 1","key":"3647_CR73","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1472-6483(11)60007-2","volume":"22","author":"C Alviggi","year":"2011","unstructured":"Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Who needs LH in ovarian stimulation? Reprod Biomed Online. 2011;22(Suppl 1):S33-41. https:\/\/doi.org\/10.1016\/S1472-6483(11)60007-2.","journal-title":"Reprod Biomed Online"},{"issue":"11","key":"3647_CR74","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/09513590.2014.932342","volume":"30","author":"E Papaleo","year":"2014","unstructured":"Papaleo E, Vanni VS, Vigano P, La Marca A, Pagliardini L, Vitrano R, et al. Recombinant LH administration in subsequent cycle after \u201cunexpected\u201d poor response to recombinant FSH monotherapy. Gynecol Endocrinol. 2014;30(11):813\u20136. https:\/\/doi.org\/10.3109\/09513590.2014.932342.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"3647_CR75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.rbmo.2015.06.002","volume":"31","author":"HM Behre","year":"2015","unstructured":"Behre HM, Howles CM, Longobardi S, Investigators PS. Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation. Reprod Biomed Online. 2015;31(3):339\u201346. https:\/\/doi.org\/10.1016\/j.rbmo.2015.06.002.","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"3647_CR76","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dew360","volume":"32","author":"P Humaidan","year":"2017","unstructured":"Humaidan P, Chin W, Rogoff D, D\u2019Hooghe T, Longobardi S, Hubbard J, et al. Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017;32(3):544\u201355. https:\/\/doi.org\/10.1093\/humrep\/dew360.","journal-title":"Hum Reprod"},{"issue":"2","key":"3647_CR77","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00404-023-07309-w","volume":"309","author":"JC Chang","year":"2024","unstructured":"Chang JC, Yi YC, Chen YF, Guu HF, Kung HF, Chen LY, et al. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol. Arch Gynecol Obstet. 2024;309(2):699\u2013706. https:\/\/doi.org\/10.1007\/s00404-023-07309-w.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"3647_CR78","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/humrep\/dead226","volume":"39","author":"K Ben Messaoud","year":"2024","unstructured":"Ben Messaoud K, Bouyer J, Guibert J, de La Rochebrochard E. The burden of very early dropout in infertility care: a nationwide population-based cohort study. Hum Reprod. 2024;39(1):102\u20137. https:\/\/doi.org\/10.1093\/humrep\/dead226.","journal-title":"Hum Reprod"},{"issue":"6","key":"3647_CR79","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.fertnstert.2018.02.130","volume":"109","author":"AD Domar","year":"2018","unstructured":"Domar AD, Rooney K, Hacker MR, Sakkas D, Dodge LE. Burden of care is the primary reason why insured women terminate in vitro fertilization treatment. Fertil Steril. 2018;109(6):1121\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.02.130.","journal-title":"Fertil Steril"},{"issue":"2","key":"3647_CR80","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/rmb2.12377","volume":"20","author":"M Hirakawa","year":"2021","unstructured":"Hirakawa M, Usui E, Mitsuyama N, Oshio T. Chances of pregnancy after dropping out from infertility treatments: evidence from a social survey in Japan. Reprod Med Biol. 2021;20(2):246\u201352. https:\/\/doi.org\/10.1002\/rmb2.12377.","journal-title":"Reprod Med Biol"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-025-03647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-025-03647-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-025-03647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:14:16Z","timestamp":1765804456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-025-03647-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":80,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1007\/s10815-025-03647-7","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This opinion survey did not encompass any patient data or experiments on human participants. Under the terms of the French legislation, the study did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"With regard to the submitted work, all authors received an honorarium from Merck Serono SAS (Lyon, France; an affiliate of Merck KGaA, Darmstadt, Germany) for participation in the Delphi consensus meetings.Outside the submitted work, IC has received research grants and honoraria from Merck, Organon, Theramex, IBSA, and Gedeon Richter.JL has received research grants and honoraria from Merck, Gedeon Richter, Theramex, IBSA, and Ferring.CCB, VdB, SP, and ML are salaried employees of Merck Serono SAS France, an affiliate of Merck KGaA, Darmstadt, Germany.TC and SB are salaried employees of CEMKA.BS has received research grants and honoraria from G\u00e9deon Richter.FO has received research grants and honoraria from Merck and G\u00e9d\u00e9on Richter.LJ has received research grants and honoraria from Merck, G\u00e9d\u00e9on Richter, and Ferring.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}]}}